InMode (NASDAQ:INMD) Price Target Lowered to $26.00 at Barclays

InMode (NASDAQ:INMD) had its price target lowered by Barclays from $27.00 to $26.00 in a report issued on Thursday,Benzinga reports. The firm currently has an overweight rating on the healthcare company’s stock.

INMD has been the topic of a number of other reports. BTIG Research began coverage on InMode in a research note on Thursday, October 17th. They issued a “buy” rating and a $25.00 price objective on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a report on Thursday, October 31st. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $22.40.

InMode Price Performance

InMode stock opened at $16.01 on Thursday. InMode has a one year low of $14.87 and a one year high of $26.80. The company’s fifty day moving average price is $18.09 and its two-hundred day moving average price is $17.32. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of 8.65 and a beta of 2.12.

Institutional Trading of InMode

Hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC raised its holdings in InMode by 314.7% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company’s stock valued at $60,000 after acquiring an additional 2,694 shares in the last quarter. Quarry LP lifted its position in InMode by 154.3% in the third quarter. Quarry LP now owns 3,781 shares of the healthcare company’s stock worth $64,000 after purchasing an additional 2,294 shares during the period. National Bank of Canada FI increased its holdings in InMode by 40.7% in the 2nd quarter. National Bank of Canada FI now owns 9,406 shares of the healthcare company’s stock valued at $168,000 after buying an additional 2,720 shares during the period. GW Henssler & Associates Ltd. bought a new stake in InMode in the 3rd quarter valued at $177,000. Finally, DGS Capital Management LLC bought a new position in shares of InMode during the 3rd quarter worth about $182,000. 68.04% of the stock is owned by institutional investors.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.